Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 4/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740939 | 0.89 | KDM1A (0.51) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL10779358 | 0.87 | MAPT (0.62) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL10659225 | 0.76 | MAPT (0.78) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL16137654 | 0.76 | PDE3B (0.51) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5768340 | 0.75 | PDE3B (0.61) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL23143482 | 0.75 | PDE3B (1.00) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL1559008 | 0.75 | MAPT (0.79) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5771609 | 0.74 | MAPT (0.77) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL16090359 | 0.74 | MAPT (0.53) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL15344913 | 0.73 | PDE3B (0.58) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | claimed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| US-20190315734-A1 | PURIFICATION METHOD FOR 5-(THIAZOL-4-YL)INDOLIN-2-ONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190315734-A1 | PURIFICATION METHOD FOR 5-(THIAZOL-4-YL)INDOLIN-2-ONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10377749-B2 | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10377749-B2 | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10377749-B2 | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2017026119-A1 | PURIFICATION METHOD FOR 5-(THIAZOLE-4-YL)INDOLINE-2-ONE DERIVATIVE | 大日本住友製薬株式会社 | 2017-02-16 | — | — | WO | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377749-B2 | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative | HRH4, CHRM2, CHRM1 | PDE3B 1758/4885PDE3A 1446/4885CYP1A2 244/4885 |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | PDE3B 380/4885PDE3A 642/4885CYP1A2 107/4885 |
| US-20190315734-A1 | PURIFICATION METHOD FOR 5-(THIAZOL-4-YL)INDOLIN-2-ONE DERIVATIVE | HRH4, CHRM2, CHRM1 | PDE3B 1758/4885PDE3A 1446/4885CYP1A2 244/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | PDE3B 79/4885PDE3A 262/4885CYP1A2 62/4885 |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | PDE3B 380/4885PDE3A 642/4885CYP1A2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.